Close
CDMO Safety Testing 2026
Novotech

Thermo Fisher launches IonicX XRF Analyzer to identity ionic salts

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Quantum Computing Enhancing Clinical Trial Design

The modernization of clinical development is undergoing a massive shift as quantum-based optimization tools are integrated into trial architectures. By improving patient selection and simulating physiological responses at a molecular level, these technologies are reducing the high failure rates associated with traditional research phases. This evolution toward digital and adaptive trials ensures that therapeutic candidates are tested more efficiently, leading to faster regulatory approvals and a more streamlined path for delivering life-saving treatments to the public.

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Teva Adds Ecopipam Therapy in $700M Emalex Acquisition Deal

Teva Pharmaceuticals has entered into a definitive agreement to...
- Advertisement -

Thermo Fisher Scientific has launched a new handheld X-ray fluorescence analyser called IonicX XRF Analyzer to help pharmaceutical and biopharmaceutical manufacturers to verify the identity of ionic salts in warehouses within seconds.

According to the life sciences company, the technology used by the IonicX XRF Analyzer helps save time and money that is otherwise used on conventional analysis techniques. This is achieved by directly putting laboratory-grade capabilities into the hands of raw material and quality control managers irrespective of their location in the manufacturing facility, said Thermo Fisher.

The IonicX handheld XRF analyser is said to have the capability to identify and authenticate the five most-used salts in biopharmaceutical and pharmaceutical manufacturing. Included in these are sodium chloride (NaCl), potassium chloride (KCl), magnesium chloride (MgCl2), calcium chloride (CaCl2) and sodium hydroxide (NaOH).

As per Thermo Fisher, the capability to identify the salts can bring down the time and cost of pharmaceutical materials testing and at the same time will help in keeping up with regulatory compliance and rigorous quality standards.

The IonicX XRF Analyzer is claimed to adhere to good manufacturing practices (GMP) and the 21 CFR Part 11 requirements. Specifically designed for the pharmaceutical industry, the X-ray fluorescence analyser is said to be easy-to-use, portable, fast, and needs minimal sample preparation according to Thermo Fisher.

The wi-fi enabled IonicX XRF Analyzer is designed to be lightweight and its small footprint enables easy portability.

Thermo Fisher product manager Kyle Dumke said: โ€œCompliance and efficiency are top concerns for raw materials managers, but thoroughly analyzing all incoming materials takes time and resources.

โ€œPharmaceutical companies purchase these salts in large amounts and are required to test each container to meet strict regulatory requirements. Thatโ€™s a tedious and costly process when using standard wet chemistry lab or near-infrared (NIR) benchtop testing. With a portable XRF analyzer, testing can be done right on the warehouse floor in seconds.โ€

Earlier this month, Thermo Fisher wrapped up its previously announced acquisition of an active pharmaceutical ingredient (API) manufacturing plant from GlaxoSmithKline (GSK) located in the Cork, Ireland. The acquisition will help expand its API manufacturing capabilities, said Thermo Fisher.

Latest stories

Related stories

Quantum Computing Enhancing Clinical Trial Design

The modernization of clinical development is undergoing a massive shift as quantum-based optimization tools are integrated into trial architectures. By improving patient selection and simulating physiological responses at a molecular level, these technologies are reducing the high failure rates associated with traditional research phases. This evolution toward digital and adaptive trials ensures that therapeutic candidates are tested more efficiently, leading to faster regulatory approvals and a more streamlined path for delivering life-saving treatments to the public.

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Teva Adds Ecopipam Therapy in $700M Emalex Acquisition Deal

Teva Pharmaceuticals has entered into a definitive agreement to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป